目的 探寻硫酸软骨素与艾瑞昔布联合方案在膝关节骨性关节炎患者中的综合疗效及安全性，以期为临床实践中该阶段患者的药物联合治疗提供依据。方法 回顾性分析2023年8月—2025年7月在内蒙古医科大学第二附属医院治疗的90例膝关节骨性关节炎患者，依据治疗方式的差异分为对照组（44例）和治疗组（46例）。对照组给予口服艾瑞昔布片，0.1 g/次，2次/d。治疗组在对照组治疗基础上口服硫酸软骨素片，3片/次，3次/d。两组均连续治疗12周。观察两组临床疗效，比较两组视觉模拟评分（VAS）、国际膝关节文献委员会主观膝关节评估表（IKDC）评分、美国特种外科医院膝关节评分（HSS）、健康调查简表36（SF-36）、血清Ⅱ型胶原蛋白羧基端端肽（CTX-Ⅱ）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）。结果 治疗后，治疗组总有效率是95.65%，显著高于对照组的79.55%（P＜0.05）。治疗后，两组静息VAS、行走VAS评分均较前显著降低，而IKDS评分升高（P＜0.05）；治疗后，与对照组相比，治疗组静息VAS与行走VAS评分均更低，IKDS评分更高（P＜0.05）。治疗后，两组HSS量表中疼痛、功能、活动范围、肌力、屈曲畸形、稳定性评分及总评分均显著升高（P＜0.05）；治疗后，治疗组HSS量表各维度评分及总评分均高于对照组（P＜0.05）。治疗后，两组SF-36量表生理职能、生理功能、躯体疼痛及总体健康、活力、情感职能、精神健康及社会功能各维度评分均显著升高（P＜0.05）；治疗后治疗组SF-36各维度评分均高于对照组（P＜0.05）。治疗后，两组患者CTX-Ⅱ、TNF-α、IL-6水平均较治疗前显著下降（P＜0.05）；治疗组治疗后CTX-Ⅱ、TNF-α、IL-6水平低于对照组（P＜0.05）。结论 硫酸软骨素联合艾瑞昔布治疗膝关节骨性关节炎可显著提高临床疗效，降低疼痛感，提高生活质量与膝关节功能，减轻炎症反应。

Objective To investigate the comprehensive efficacy and safety of chondroitin sulfate combined with imrecoxib in treatment of knee osteoarthritis, and to provide evidence for combined pharmacotherapy in this patient population in clinical practice. Methods A retrospective analysis was conducted on 90 patients with knee osteoarthritis who were treated at Second Affiliated Hospital of Inner Mongolia Medical University from August 2023 to July 2025. These patients were divided into control group (44 cases) and treatment group (46 cases) based on the differences in treatment methods. Patients in control group were given oral Imrecoxib Tablets at a dose of 0.1 g each time, twice daily. Patients in treatment group were given oral Chondroitin Sulfate Tablets at a dose of 3 tablets each time in addition to treatment received by control group, three times daily. Both groups were treated continuously for 12 weeks. The clinical efficacy of two groups was observed, and visual analogue scale (VAS) scores, subjective knee joint assessment form of International Knee Joint Committee (IKDC) scores, Hospital for Special Surgery knee score (HSS), 36-Item Short Form Health Survey (SF-36), serum type II collagen carboxy-terminal peptide (CTX-II), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) of two groups were compared. Results After treatment, the total effective rate of treatment group was 95.65%, significantly higher than that of control group (79.55%, P < 0.05). After treatment, the resting VAS and walking VAS scores of both groups were significantly lower than before, while the IKDS score increased (P < 0.05). After treatment, compared with the control group, the resting VAS and walking VAS scores of the treatment group were lower, and the IKDS score was higher (P < 0.05). After treatment, the scores of the HSS scale in pain, function, range of motion, muscle strength, flexion deformity, stability, and total score of both groups significantly increased (P < 0.05). After treatment, the scores of each dimension and total score of the HSS scale in treatment group were higher than those of control group (P < 0.05). After treatment, the scores of the SF-36 scale in physical function, physiological function, physical pain, overall health, vitality, emotional function, mental health, and social function of both groups significantly increased (P < 0.05). After treatment, the scores of each dimension of the SF-36 scale in treatment group were higher than those of control group (P< 0.05). After treatment, the levels of CTX-II, TNF-α, and IL-6 in both groups were significantly lower than those before treatment (P < 0.05). The levels of CTX-II, TNF-α, and IL-6 in treatment group after treatment were lower than those in control group (P < 0.05). Conclusion The combination of chondroitin sulfate combined with imrecoxib in treatment of knee osteoarthritis can significantly improve clinical efficacy, reduce pain, enhance life quality and knee joint function, and alleviate inflammatory responses.

R977

内蒙古自治区科技计划项目（2025YFSH0111）